PE491A1 - Novedosa forma galenica oral que mejora la biodisponibilidad - Google Patents

Novedosa forma galenica oral que mejora la biodisponibilidad

Info

Publication number
PE491A1
PE491A1 PE1990173269A PE17326990A PE491A1 PE 491 A1 PE491 A1 PE 491A1 PE 1990173269 A PE1990173269 A PE 1990173269A PE 17326990 A PE17326990 A PE 17326990A PE 491 A1 PE491 A1 PE 491A1
Authority
PE
Peru
Prior art keywords
novel oral
improves bioavailability
active element
gallenic
gallenic form
Prior art date
Application number
PE1990173269A
Other languages
English (en)
Inventor
Jean-Marc Aiache
Denis Besancon
Original Assignee
Laboratoires Delagrange
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Delagrange filed Critical Laboratoires Delagrange
Publication of PE491A1 publication Critical patent/PE491A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

BUSCA LA MEJORA DE LA DISPONIBILIDAD BIOLOGICA DE UN MEDICAMENTO TRATANDO QUE; CON UNA SOLA TOMA AL DIA, SE LOGRE LIBERAR EL ELEMENTO ACTIVO EN FORMA PROGRESIVA DURANTE LAS SIGUIENTES 24 HORAS, Y AL MISMO TIEMPO BUSCANDO UN MAXIMO APROVECHAMIENTO DE ESTE ELEMENTO ACTIVO. SE LOGRA ESTO, DE ACUERDO CON LO QUE SE SOLICITA, POR LA PRESENCIA EN LA FORMULACION DE PROTEINAS NATURALES, EN ESPECIAL LAS DERIVADAS DE LA LECHE DESNATADA. SE HACE DE ESTE SISTEMA A PASTILLAS QUE CONTIENE PRINCIPIOS INHIBIDORES DEL CALCIO, TALES COMO LA DIHIDROPIRIDINA, LA OXODIPINA Y LA NIFEDIPINA
PE1990173269A 1989-08-07 1990-08-03 Novedosa forma galenica oral que mejora la biodisponibilidad PE491A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8910605A FR2650502B1 (fr) 1989-08-07 1989-08-07 Nouvelle forme galenique orale ameliorant la biodisponibilite

Publications (1)

Publication Number Publication Date
PE491A1 true PE491A1 (es) 1991-01-26

Family

ID=9384532

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1990173269A PE491A1 (es) 1989-08-07 1990-08-03 Novedosa forma galenica oral que mejora la biodisponibilidad

Country Status (25)

Country Link
EP (1) EP0412877A1 (es)
JP (1) JPH0377819A (es)
KR (1) KR910004181A (es)
CN (1) CN1049455A (es)
AU (1) AU631235B2 (es)
CA (1) CA2022447A1 (es)
CS (1) CS383890A3 (es)
DD (1) DD297332A5 (es)
DE (1) DE4023136A1 (es)
FI (1) FI903885A7 (es)
FR (1) FR2650502B1 (es)
GB (1) GB2234898A (es)
HU (1) HU204997B (es)
IE (1) IE902629A1 (es)
IL (1) IL95105A0 (es)
IN (1) IN170789B (es)
LU (1) LU87777A1 (es)
MA (1) MA21923A1 (es)
NO (1) NO903442L (es)
NZ (1) NZ234593A (es)
OA (1) OA09301A (es)
PE (1) PE491A1 (es)
PT (1) PT94823A (es)
TN (1) TNSN90111A1 (es)
ZA (1) ZA905886B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0701815B1 (de) * 1992-01-17 1999-06-30 ALFATEC-PHARMA GmbH Verfahren zur Herstellung von Wirkstoff enthaltenden Pulvern, Granulaten oder Pellets mit einem Gerüst aus hydrophilen Makromolekülen und ihre Verwendung
DE4221880A1 (de) * 1992-07-03 1994-01-05 Alfatec Pharma Gmbh Feste und flüssige Lösungen von schwer wasserlöslichen Arzneistoffen
KR20030089147A (ko) * 2002-05-16 2003-11-21 슈라펫 주식회사 애완동물용 급수통

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE854414C (de) * 1949-04-26 1952-11-04 Dieter Dr Med Ellenbeck Verfahren zur Herstellung von injizierbaren Loesungen von an sich mehr oder weniger schwer loeslichen Arzneimitteln
GB715874A (en) * 1952-10-03 1954-09-22 Horlicks Ltd A tablet for use in treating peptic ulcers
GB906422A (en) * 1958-05-02 1962-09-19 Wellcome Found Improvements in and relating to prolonged acting pharmaceutical preparations
US3015611A (en) * 1959-08-25 1962-01-02 Nysco Lab Inc Low density whey-bound tablets
GB1063872A (en) * 1962-08-11 1967-03-30 Wellcome Found Improvements in and relating to prolonged acting pharmaceutical compositions
US3594467A (en) * 1968-10-09 1971-07-20 Richardson Merrell Inc Long-lasting troche
US3922379A (en) * 1973-12-17 1975-11-25 Abbott Lab Microencapsulation process
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
CA1184492A (en) * 1981-01-14 1985-03-26 Masataka Morishita Preparation having excellent absorption property
FR2524312B1 (fr) * 1982-04-01 1985-10-04 Tech Cuir Centre Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
US4670251A (en) * 1984-05-30 1987-06-02 Igene Biotechnology, Inc. Microcrystalline tableting excipient derived from whey
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
IL78017A (en) * 1986-03-03 1989-06-30 Yissum Res Dev Co Sustained release tablets of theophylline
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
US5051406A (en) * 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
CA1324083C (en) * 1987-03-09 1993-11-09 Tetsu Miyoshi Pharmaceutical preparations containing non-steroidal anti-inflammatory agents
DK179687D0 (da) * 1987-04-08 1987-04-08 Farma Food As Praeparat
ATE90205T1 (de) * 1987-09-08 1993-06-15 Takeda Chemical Industries Ltd Wasserunloesliche cytokine.

Also Published As

Publication number Publication date
FI903885A0 (fi) 1990-08-06
GB2234898A (en) 1991-02-20
GB9017144D0 (en) 1990-09-19
NO903442D0 (no) 1990-08-06
CA2022447A1 (fr) 1991-02-08
NO903442L (no) 1991-02-08
HU904909D0 (en) 1991-01-28
IL95105A0 (en) 1991-06-10
AU631235B2 (en) 1992-11-19
CS276556B6 (en) 1992-06-17
FR2650502A1 (fr) 1991-02-08
OA09301A (fr) 1992-09-15
MA21923A1 (fr) 1991-04-01
NZ234593A (en) 1993-04-28
IN170789B (es) 1992-05-23
JPH0377819A (ja) 1991-04-03
EP0412877A1 (fr) 1991-02-13
FR2650502B1 (fr) 1994-05-27
DE4023136A1 (de) 1991-02-14
CN1049455A (zh) 1991-02-27
HUT55230A (en) 1991-05-28
ZA905886B (en) 1991-04-24
FI903885A7 (fi) 1991-02-08
IE902629A1 (en) 1991-02-27
HU204997B (en) 1992-03-30
DD297332A5 (de) 1992-01-09
LU87777A1 (fr) 1990-12-11
CS383890A3 (en) 1992-06-17
AU6023990A (en) 1991-02-07
TNSN90111A1 (fr) 1991-03-05
PT94823A (pt) 1991-04-18
KR910004181A (ko) 1991-03-28

Similar Documents

Publication Publication Date Title
ES2181723T3 (es) Formulaciones farmaceuticas de factor de crecimiento nervioso.
DE60019122D1 (de) Veränderter faktor viii
DE3872372D1 (de) Zusammensetzung zur erhoehung der intrazell-atp-spiegel und des physischen leistungsniveaus und zur erhoehung der geschwindigkeit von wundenheilung.
BR9801126A (pt) 1,4-benzotiazepina-1,1-dióxidos hipolipidêmicos.
MX9203543A (es) Medicamento.
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
UA41265C2 (uk) Кристалічна форма (-)-цис-4-аміно-1-(2-гідроксиметил-1,3-оксатіолан-5-іл)-(1н)-піримідин-2-ону (варіанти), способи її отримання та фармацевтична композиція
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
DE59102210D1 (de) Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus.
ES2052583T3 (es) Derivados de peptidos relacionados con el gel calcitonina.
DE3878313D1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
MX9301535A (es) Material proteinaceo biologicamente activo aislado y purificado.
ES2133295T3 (es) Peptidos ciclicos y su uso.
PE491A1 (es) Novedosa forma galenica oral que mejora la biodisponibilidad
ATE80295T1 (de) Fettsaeure und cyclosporin enthaltende zusammensetzung mit ermaessigter nephrotoxizitaet.
DE68914930D1 (de) Naphtochinone zur Behandlung und Prophylaxe von Pneumocystis carinii-Infektionen.
DE69627340D1 (de) Transformierenden waeckstumsfaktor beta krystalle
ES2134237T3 (es) Composiciones farmaceuticas que contienen acido ursodesoxicolico.
ATE110723T1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
ES2118726T3 (es) Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos.
BR0202681A (pt) Compostos de octaidro-2h-pirido[1,2a]pirazina, um processo para sua preparação e composições farmacêuticas contendo-as
ES2072332T3 (es) Derivados de la dibenzo(1,5)dioxocin-5-ona, su uso en medicamentos y procedimiento para su fabricacion.
ATE160090T1 (de) Verwendung von l-carnitine und acyl-l-carnitinen zur behandlung von patienten die an aids- verwandten syndromen leiden und von asymptomatischen hiv-seropositiven patienten
PT84996A (de) Pharmazeutische zubereitung zur behandlung bakterieller infektionen